Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Avacopan (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CLASSIC
- Sponsors ChemoCentryx
- 14 Nov 2022 Results of pooled analysis (n=439) assessing the safety of avacopan from two Phase 2 (CLEAR and CLASSIC) and one Phase 3 studies (ADVOCATE) in patients with ANCA-Associated Vasculitis, presented at the ACR Convergence 2022.
- 11 Apr 2018 Accoridng to ChemoCentryx media release, safety, renal parameters and quality of life outcomes from this study are being presented during the 2018 Spring Clinical Meetings of the National Kidney Foundation (NKF).
- 07 Nov 2016 Accoridng to ChemoCentryx media release, positive results will be presented at the American Society of Nephrology (ASN) Kidney Week 2016